Flush with cash amid Philips recall, ResMed drops $1B on German software developer Health IT execs skeptical of Oracle's lofty vision to build national medical records system Did J&J and BMS conspire on blood thinner price hikes? Congressional leaders want DOJ, FTC to look into it: report Taking Charge—biotechs already approaching Novartis to partner on 'game changing' CAR-T platform Siemens' next-generation SPECT/CT scanner captures FDA clearance The top 10 most profitable pharma companies in 2021 BridgeBio bounces back? Phase 2 readout provides hope for approval of drug to rebalance calcium levels AMA sets out major positions on abortion, climate change and disinformation at annual meeting Machine learning model predicts intracranial hemorrhage in head trauma patients: study Bavarian Nordic's revenue forecast jumps—again—after fresh monkeypox vaccine order with Europe Biotech edges toward gender parity, but C-suites stay male, white Lensar eyes launch of AR-assisted cataract surgery system after FDA clearance Alnylam's next-gen RNA drug Amvuttra wins FDA approval—and a Pfizer showdown may await FTC requests additional details on UnitedHealth's acquisition of LHC Group Featured Story | By Andrea Park The additional revenue that ResMed has picked up in the wake of competitor Philips’ long-lasting ventilator recall appears to be burning a hole in the devicemaker’s pocket. read more |
| |
|---|
|
Top Stories By Heather Landi Oracle chairman Larry Ellison's vision to use the power of Cerner to build a national health records database is a lofty ambition, health IT professionals say, but it's an aspiration that will take an unprecedented level of industry collaboration to execute. read more By Kevin Dunleavy Sen. Amy Klobuchar and Rep. Katie Porter are asking the Department of Justice and the Federal Trade Commission to probe whether price hikes for Bristol Myers Squibb's Eliquis and Johnson & Johnson's Xarelto were illegally orchestrated by the companies. Medicare spent more on Eliquis than any other drug in 2020, while the spend on Xarelto was the third most in the system. read more By James Waldron With the first generation of CAR-T therapies having shaken up the cancer space, all eyes are on what comes next. So it shouldn’t be a surprise that biotechs have already been in touch with Novartis to see whether they can jump onto the Swiss pharma’s T-Charge platform. read more By Conor Hale Siemens Healthineers received clearance from the FDA for its latest scanner that combines SPECT and CT imaging into a comparatively smaller package. read more By Angus Liu,Eric Sagonowsky,Kevin Dunleavy,Fraiser Kansteiner,Zoey Becker While revenue reflects how well a pharma company’s products and services are selling, profit represents another important measurement that provides investors a look at the health of the business and how efficiently it has been managed. Here, we rank the top 10 pharma companies by 2021 net income. read more By Gabrielle Masson After a series of unfortunate events for BridgeBio Pharma, the biotech may be on a new upward trajectory as it unveiled positive data from 13 patients taking a drug to treat low calcium levels. read more By Heather Landi At its annual meeting in Chicago this week, the AMA's delegates voted to adopt resolutions that oppose state-level measures to criminalize abortion and other reproductive care services, either by penalizing patients or physicians. read more By Andrea Park With a slew of FDA nods this year alone, artificial intelligence can now be widely used in hospital settings to quickly detect the presence of bleeding within the skull or brain. But a new AI tool is aiming to spot signs of internal bleeding much earlier, before a person with head trauma has even arrived at the hospital. read more By Fraiser Kansteiner For Bavarian Nordic, Tuesday brought another tranche of European monkeypox vaccine orders—and with it, the second recent boost to the Danish drugmaker’s 2022 revenue forecast. read more By Nick Paul Taylor Biotech’s slow shuffle toward increased representation of women and employees of color continued in 2021, with BIO’s third annual survey revealing progress but also the need for further improvements. read more By Andrea Park With the FDA’s nod, Lensar said it will begin rolling out the Ally adaptive cataract treatment system in a small-scale initial launch in the third quarter of this year. After that, it’ll expand into a wider commercial launch for U.S. cataract surgeons in 2023. read more By Angus Liu Alnylam’s closely watched Onpattro follow-on therapy, vutrisiran, has snagged a much-anticipated FDA green light. The approval tees up a possible showdown with Pfizer’s blockbuster Vyndaqel franchise in an increasingly competitive rare disease field. read more By Paige Minemyer The Federal Trade Commission has issued a second request for information on UnitedHealth Group's $5 billion planned acquisition of home health provider LHC Group. read more | 